Do you want to read an article? Please log in or register.
Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
Multiple Sclerosis
RECOMMENDED
Related content
Multiple Sclerosis
The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
PLoS One.
Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G
doi: 10.1371/
Multiple Sclerosis
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)
doi: 10.1111/ene.13594.
Multiple Sclerosis
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
Mult Scler.
Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P
doi: 10.1177/1352458519881759.
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
SPECIAL REPORT
Multiple Sclerosis
Vaccination Readiness in Multiple Sclerosis
COMMENTED
Multiple Sclerosis
The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research
BMC Neurol.
Steinemann N, Kuhle J, Calabrese P, Kesselring J, Disanto G, Merkler D, Pot C, Ajdacic-Gross V, Rodgers S, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry
doi: 10.1186/s12883-018-1118-0.
Multiple Sclerosis
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
Mult Scler Relat Disord.
Liu Y, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Wang P, Sabatella G
doi: 10.1016/j.msard.2016.11.005.
RECOMMENDED
Multiple Sclerosis
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
Mult Scler.
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R
doi: 10.1177/1352458519881761.
Aging and Cognitive FunctionsMultiple Sclerosis
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
Mult Scler.
Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, Elkins J, Sabatella G
doi: 10.1177/1352458517707345.